Skip to main content

Premier to Offer Members Access to Meridian's Illumigene MDx Tests

NEW YORK (GenomeWeb) – Meridian Bioscience today announced an agreement with healthcare alliance Premier to offer Meridian's illumigene molecular tests.

Premier serves more than 3,000 hospitals and 110,000 other healthcare sites. Under the agreement, Premier facilities will offer Meridian's tests for C. difficile, Group A and B Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene platform, which uses loop-mediated isothermal DNA amplification technology to provide results in less than one hour.

Financial and other terms of the deal were not disclosed.

On Tuesday, Meridian provided fiscal year 2015 revenue and earnings-per-share guidance that came in below consensus Wall Street estimates.

Charlotte, NC-based Premier provides a range of products and services to healthcare providers to improve outcomes and contain costs.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.